Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis

Inclusion Criteria:

* Female patients. It should be noted that LAM occurs almost exclusively in women.
* 18 to 65 years of age.
* All patients must have a diagnosis of LAM as defined by compatible cystic changes on chest computed tomography (CT) and one of the following:
* Open lung, transbronchial or thoracic needle biopsy consistent with LAM
* Open or needle abdominal biopsy findings consistent with LAM
* Clinical findings of tuberous scleroma complex (TSC), renal angiomyolipoma, cystic abdominal lymphangiomas, or history of chylous effusion in the chest or abdomen
* Serum vascular endothelial growth factor D (VEGF-D) \> 800 pg/ml
* Subjects must have had a recent reduction in forced expiratory volume at 1-second (FEV1) of \> 50ml/year, as shown by at least two pulmonary function testing (PFT) measured at least 6 months apart in the last 24 months prior to enrolling study.

Exclusion Criteria:

* Current infection.
* Major surgery within the past 2 months
* Advanced hematologic, renal, hepatic, non-LAM lung disease or metabolic diseases; or BMI of \>35
* The use of another investigational drug within 30 days
* The use of mTOR (mammalian target of rapamycin) inhibitors within 30 days
* Previous lung transplantation.
* Inability to attend scheduled clinic visits
* Inability to give informed consent
* Inability to perform pulmonary function testing
* History of malignancy in the past two years, other than squamous or basal cell skin cancer or status post successful excision or treatment.
* Nursing mothers
* Current or planned pregnancy.
* Not using adequate contraception (in woman of childbearing potential).
* Significant clinical change in health in the past 30 days